When is standard treatment sufficiently active to make use of a placebo-controlled trial unethical?
- PMID: 20856725
- PMCID: PMC2790645
- DOI: 10.1200/JOP.0922503
When is standard treatment sufficiently active to make use of a placebo-controlled trial unethical?
Abstract
Research has demonstrated that double blinding can lessen the potential for bias in study outcomes, such as perceiving a drug as more effective in the experimental arm of a study. Effective double-blinding techniques minimize the influence of investigator and patient expectations.
References
-
- Fossati R, Confalonieri C, Apolone G, et al: Does a drug do better when it is new? Ann Oncol 13:470-473, 2002 - PubMed
-
- Barbui C, Cipriani A, Brambilla P, et al: “Wish bias” in antidepressant drug trials? J Clin Psychopharmacol 24:126-130, 2004 - PubMed
-
- Daugherty CK, Ratain MJ, Emanuel EJ, et al: Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol 26:1371-1387, 2008 - PubMed
LinkOut - more resources
Full Text Sources